Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients

Brief summary (registry, in English)

Vifor International Inc. is seeking real-world evidence (RWE) to better understand the epidemiology, patient characteristics, and management of CKD-aP in the real-world clinical setting.

What you commit to

• Study type: Observational
• Participants enrolled: 3100
• From 2 Feb 2023 to the primary completion date, 31 Jan 2024
• 94 sites in 7 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (94)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Related publications

• Prevalence and burden of chronic kidney disease-associated pruritus in Europe (CENSUS-EU).J Nephrol · 2026 · PMID 42290117
• Prevalence, severity, and determinants of CKD-associated pruritus in a Swiss hemodialysis population with widespread use of hemodiafiltration: a cross-sectional study.BMC Nephrol · 2025 · PMID 41249950